Bropirimine
Product Specifications
UNSPSC Description
Bropirimine is a synthetic agonist for toll-like receptor 7 (TLR7). Bropirimine inhibits differentiation of osteoclast precursor cells into osteoclasts via TLR7-mediated production of IFN-β. Bropirimine is an orally active immunomodulator that has demonstrated anticancer activity in transitional cell carcinoma in situ (CIS) in both the bladder and upper urinary tract[1][2].
Target Antigen
Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bropirimine.html
Purity
99.92
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1NC(N)=NC(C2=CC=CC=C2)=C1Br
Molecular Weight
266.098
References & Citations
[1]Suzuki H, et al. Bropirimine inhibits osteoclast differentiation through production of interferon-β. Biochem Biophys Res Commun. 2015;467(1):146‐151.|[2]Sarosdy MF, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Urology. 1998;51(2):226‐231.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-W008634/Bropirimine-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-W008634/Bropirimine-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
56741-95-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MD-B0.5+1.5 1 Each
Combination: for 0.5 mL tube, 12 wells; and for 1.5 mL tube, 12 wells (on the same side)
Ask
View Details 